Email Updates

You are here

Home

22 DECEMBER 2022 VOLUME 24 ISSUE 51

Media Coverage

  • Experts Harp on HIV Prevention Tools To Mitigate Virus Spread

    With recent reports showing a rise in new Human Immuno-deficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) cases in the country, public health experts have called for more awareness on new and improved prevention tools to mitigate spread of the virus in line with the global campaign to end AIDS epidemic by 2030.

    December 22, 2022
    General
    The Guardian

  • US FDA Approves Gilead’s Long-Acting HIV Drug Sunlenca

    The US Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's (GILD.O) Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments. Sunlenca injection and tablets are expected to cost $42,250 in the first year of therapy and $39,000 annually after that, the company told Reuters.

    December 22, 2022
    Treatment
    Reuters

  • Study Identifies Barriers to PrEP Uptake in Black Female Adolescents, Young Adults

    Pre-exposure prophylaxis (PrEP) significantly reduces the risk of HIV infection, but concerns about adverse effects (AEs), financial factors, and medical mistrust surrounding PrEP may limit its uptake in Black female adolescents and emerging adults (AEA), a recent study suggests.

    December 21, 2022
    PrEP
    Pharmacy Times

  • Injectable HIV Treatment Offers Hope to Ugandan Patients

    Ever since Gerald Muwonge tested positive for HIV eight years ago, keeping his viral load in check has meant carrying around vials of pills for his daily treatment regimen while dodging the stigma this could mean for a gay man in Uganda. But he hopes that could soon change thanks to an injectable treatment that only needs to be taken once every two months.

    December 21, 2022
    Treatment
    Reuters

  • Links Between Intimate Partner Violence and HIV Risk Among Transgender Women Require Trans-Affirming Health and Social Services

    Transgender women are more than 32 times more likely than cisgender adults to be living with HIV and twice as likely to experience physical and sexual violence from their intimate partners. According to recent research conducted with transgender women living in the United States, published in the journal Culture, Health & Sexuality, transgender women’s high rates of HIV and intimate partner violence are due to a number of factors.

    December 21, 2022
    General
    aidsmap

  • People With HIV Can Benefit From Lung Cancer Screening

    People living with HIV who are current or former heavy smokers may be at high risk for lung cancer and can benefit from regular screening, according to the Forum of International Respiratory Societies (FIRS), an organization consisting of the world’s leading professional respiratory societies. “As antiretrovirals have prolonged the lives of people with HIV and made it more like a chronic disease, lung cancer has emerged as a leading cause of death in smokers infected with HIV,” said American Thoracic Society president Gregory Downey, MD, in a FIRS press statement on World AIDS Day.

    December 21, 2022
    General
    POZ Magazine

  • What’s the State of HIV Cure Research as 2022 Comes to an End?

    It seems as though a day did not go by in 2022 when we didn’t see a headline suggesting that A BIG HIV CURE BREAKTHROUGH was right around the corner. So many early trials seem to be in play. And of course, we learned about the “New York patient,” the third known person to be cured of HIV via stem-cell transplantation in the course of treatment for cancer.

    December 21, 2022
    Cure
    TheBody

  • HIV/AIDS Organizations Call on US Government to Fund a National PrEP Program

    Since the release of HIV PrEP (pre-exposure prophylaxis) to the public more than 10 years ago, approximately 350,000 people have been diagnosed with HIV in the US Black and Latinx men who have sex with men, as well as Black women, have accounted for a disproportionate number of those diagnoses among their genders. This despite the fact that PrEP, when used effectively, all but eliminates a person’s risk of acquiring HIV through sex.

    December 20, 2022
    PrEP
    TheBody

  • Dr. Anthony Fauci Is Stepping Down. Here’s His Advice For His Successor

    After Dr. Anthony Fauci steps down as head of the National Institute of Allergy and Infectious Diseases (NIAID) and chief medical advisor to President Biden on Dec. 31, he’ll leave behind a long and storied career. Ahead of his last day, he spoke to TIME from his office at the National Institutes of Health about what’s next for him—and his advice for whoever fills his shoes.

    December 20, 2022
    General
    Time

  • Five Pillars of the Updated US Global AIDS Program PEPFAR

    Nearly two decades ago, the United States launched the US President’s Emergency Plan for AIDS Relief (PEPFAR), a federal program that has helped over 50 countries tackle their HIV crises. This month, PEPFAR released an updated five-year strategy to help speed up efforts to end AIDS as a global health threat by 2030.

    December 20, 2022
    General
    POZ Magazine

  • 93 Percent of Persons Living With HIV in Guyana Know Their Status

    Programme Manager of the National AIDS Programme Secretariat (NAPS), Dr Tariq Jagnarine said 93 percent of persons infected with the Human Immunodeficiency Virus (HIV) know their status. Speaking recently with the Department of Public Information (DPI), Dr Jagnarine said Guyana is close to meeting its 95-95-95 goal, set out by the Joint United Nations Programme on HIV/AIDS.

    December 19, 2022
    General
    News Room

  • Revolutionary HIV Vaccine That ‘Trains’ the Immune System Passes Its First Hurdle

    A completely new kind of vaccine that aims to induce a response to HIV that is ‘better than nature’ has completed its first immunogenicity trial in humans, with promising results. The vaccine, currently dubbed eOD-GT8, is being developed by Professor William Schief and colleagues at the Scripps Research Institute in California, in collaboration with the Fred Hutchinson Cancer Center, the International AIDS Vaccine Initiative, the US Institute of Allergies and Infectious Diseases, and a number of other research institutes.

    December 19, 2022
    HIV Vaccine
    aidsmap

  • First Cell-Type Specific Multiomic Study of the HIV Brain

    In a recent article published in the journal Molecular Cell, researchers present a valuable data resource that provides in-depth insights into cellular and genetic mechanisms governing human immunodeficiency virus (HIV) integration and expression in the human brain.

    December 19, 2022
    General
    News Medical

  • HIV Outbreak Persists as Officials Push Back Against Containment Efforts

    Brooke Parker has spent the past two years combing riverside homeless encampments, abandoned houses, and less traveled roads to help contain a lingering HIV outbreak that has disproportionately affected those who live on society's margins. She shows up to build trust with those she encounters and offers water, condoms, referrals to services, and opportunities to be tested for HIV — anything she can muster that might be useful to someone in need.

    December 19, 2022
    General
    News Medical

  • How One Country Brought Down Mother-to-Child HIV Transmission

    Philip Lokoko of the Network of People Living with HIV/AIDS in Nigeria announced the mother-to-child transmission rate of HIV has dropped to less than 10 percent in Nasarawa State. He delivered the news while discussing the Nigeria Resilient and Sustainable System for Health Project in Lafia.

    December 19, 2022
    General
    Plus Magazine

  • In West Virginia, an HIV Outbreak Persists as Officials Push Back Against Containment Efforts

    Brooke Parker has spent the past two years combing riverside homeless encampments, abandoned houses, and less traveled roads to help contain a lingering HIV outbreak that has disproportionately affected those who live on society's margins. She shows up to build trust with those she encounters and offers water, condoms, referrals to services, and opportunities to be tested for HIV — anything she can muster that might be useful to someone in need.

    December 19, 2022
    Salon

  • Long-Acting Injectable PrEP Is a Big Step Forward in HIV Prevention

    One year ago, the United States approved a new injectable drug that prevents HIV. After successful clinical trials, long-acting cabotegravir was found to be almost 100 per cent effective at preventing HIV. It was approved in the US on Dec. 20, 2021, for use as HIV pre-exposure prophylaxis (PrEP). This approval means that eligible individuals can now receive this medication every eight weeks to prevent sexually-acquired HIV infection.

    December 18, 2022
    PrEP
    The Conversation

  • Dr. Anthony Fauci on His Long Career That Spanned the AIDS and COVID Crises

    Dr. Anthony Fauci is stepping down as head of the National Institute of Allergy and Infectious Diseases. NPR's Scott Simon talks with him about a long career that spanned the AIDS and COVID crises.

    December 17, 2022
    General
    NPR

  • COVID-19 Disrupted HIV Treatment, Prevention But Trend Was Mostly Transient

    The pandemic created so many disruptions across all areas of life. And certainly health care—even areas not directly related to COVID-19—was significantly impacted. For example, HIV care saw a great reduction in testing and PrEP prescriptions. According to a recently published Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR), HIV tests declined about 32 percent between the first and second quarters of 2020, and PrEP prescriptions fell about 6 percent.

    December 16, 2022
    General
    Contagion Live

  • Texas Refuses to Expand its Medicaid to Help Combat HIV

    As Medicaid starts to enact expanded coverage in a number of states, Texas’s refusal to do so could have catastrophic outcomes for Black men who have sex with men (MSM) in Houston. The analysis, published in Medical Care, focused on HIV transmission among Black MSM between 18 to 34 years old. This disproportionately affected group accounted for 19 percent of all new diagnoses in Houston, according to News Medical.

    December 16, 2022
    General
    Plus Magazine

Published Research

Announcements